Genfit rockets on signing two deals in one day, now with Ipsen for elafibranor
Ipsen (Euronext: IPN) and fellow France-based Genfit (Euronext: GNFT) have entered into a long-term strategic partnership for global collaboration between the two companies. The agreement gives Ipsen exclusive worldwide license to develop, manufacture and commercialize Genfit’s investigational treatment elafibranor, for people living with primary biliary cholangitis (PBC).
The partnership also gives Ipsen access to future clinical programs led by Genfit and combines Genfit’s scientific expertise and proprietary technologies in liver disease with Ipsen’s development and commercialization capabilities.
This was the second deal on Friday for Genfit, which also announced a collaboration with another French biotech, Genoscience Pharma. Genfit shares closed the day up 40.8% at 4.22 euros, having reached a high of 4.64 euros in earlier trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze